These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 31494781)

  • 21. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.
    Bupathi M; Ahn DH; Wu C; Ciombor KK; Stephens JA; Reardon J; Goldstein DA; Bekaii-Saab T
    Med Oncol; 2016 Apr; 33(4):37. PubMed ID: 26995224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
    Hong E; Park S; Ooshima A; Hong CP; Park J; Heo JS; Lee S; An H; Kang JM; Park SH; Park JO; Kim SJ
    Sci Rep; 2020 Feb; 10(1):2935. PubMed ID: 32076068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
    Pelzer U; Blanc JF; Melisi D; Cubillo A; Von Hoff DD; Wang-Gillam A; Chen LT; Siveke JT; Wan Y; Solem CT; Botteman MF; Yang Y; de Jong FA; Hubner RA
    Br J Cancer; 2017 May; 116(10):1247-1253. PubMed ID: 28350787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
    Chen LT; Siveke JT; Wang-Gillam A; Li CP; Bodoky G; Dean AP; Shan YS; Jameson GS; Macarulla T; Lee KH; Cunningham D; Blanc JF; Chiu CF; Schwartsmann G; Braiteh FS; Mamlouk K; Belanger B; de Jong FA; Hubner RA
    Eur J Cancer; 2018 Dec; 105():71-78. PubMed ID: 30414528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer.
    Takada R; Ikezawa K; Yamai T; Watsuji K; Seiki Y; Kawamoto Y; Hirao T; Higashi S; Urabe M; Kai Y; Nakabori T; Uehara H; Kotani M; Yagi T; Kimura M; Nozaki K; Takagi M; Ohkawa K
    BMC Cancer; 2023 Jul; 23(1):711. PubMed ID: 37518012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study.
    Gupta A; De Jesus-Acosta A; Zheng L; Lee V; Kamel I; Le D; Pishvaian M; Laheru D
    Front Oncol; 2023; 13():1250136. PubMed ID: 37700832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
    Ueno M; Nakamori S; Sugimori K; Kanai M; Ikeda M; Ozaka M; Furukawa M; Okusaka T; Kawabe K; Furuse J; Komatsu Y; Ishii H; Sato A; Shimizu S; Chugh P; Tang R; Ioka T
    Cancer Med; 2020 Dec; 9(24):9396-9408. PubMed ID: 33099898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer.
    Smith CJ; Bekaii-Saab TS; Cook KD; Eiring RA; Halfdanarson TR; Hanna M; Jin Z; Jochum JA; Ma WW; Mitchell JL; Pitot HC; Jatoi A
    Pancreatology; 2021 Mar; 21(2):379-383. PubMed ID: 33468394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
    Mie T; Sasaki T; Okamoto T; Takeda T; Mori C; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
    Jpn J Clin Oncol; 2022 Dec; 52(12):1399-1407. PubMed ID: 36111430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial.
    Hyung J; Kim I; Kim KP; Ryoo BY; Jeong JH; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Yoo C
    JAMA Oncol; 2023 May; 9(5):692-699. PubMed ID: 36951834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials.
    Merz V; Messina C; Zecchetto C; Quinzii A; Frisinghelli M; Trentin C; Salati M; Caffo O; Melisi D
    Clin Oncol (R Coll Radiol); 2024 Feb; 36(2):87-97. PubMed ID: 38129199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: A systematic review and meta-analysis.
    Chen BS; Chan SY; Bteich F; Kuang C; Meyerhardt JA; Ma KS
    Crit Rev Oncol Hematol; 2024 Sep; 201():104386. PubMed ID: 38735505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
    Furuse J; Ueno M; Ikeda M; Okusaka T; Teng Z; Furuya M; Ioka T
    Jpn J Clin Oncol; 2023 Jan; 53(2):130-137. PubMed ID: 36412114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study.
    Kobayashi S; Tezuka S; Yamachika Y; Tsunoda S; Nagashima S; Tozuka Y; Fukushima T; Morimoto M; Ueno M; Furuse J; Maeda S
    BMC Cancer; 2023 Feb; 23(1):177. PubMed ID: 36809997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.
    Macarulla Mercadé T; Chen LT; Li CP; Siveke JT; Cunningham D; Bodoky G; Blanc JF; Lee KH; Dean A; Belanger B; Wang-Gillam A
    Pancreas; 2020 Jan; 49(1):62-75. PubMed ID: 31856081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience.
    Yu HY; Lee CY; Lin LG; Chao Y; Li CP
    J Chin Med Assoc; 2022 Jan; 85(1):42-50. PubMed ID: 34759212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
    Procaccio L; Merz V; Fasano M; Vaccaro V; Giommoni E; Pretta A; Noventa S; Satolli MA; Giordano G; Zichi C; Pinto C; Zecchetto C; Barsotti G; De Vita F; Milella M; Antonuzzo L; Scartozzi M; Zaniboni A; Spadi R; Casalino S; Bergamo F; De Toni C; Melisi D; Lonardi S
    Cancer Med; 2023 Jul; 12(13):14337-14345. PubMed ID: 37278395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort.
    Su YY; Chiang NJ; Tsai HJ; Yen CJ; Shan YS; Chen LT
    Sci Rep; 2020 May; 10(1):7420. PubMed ID: 32366911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
    Ur Rehman SS; Lim K; Wang-Gillam A
    Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs.
    Milano G; Innocenti F; Minami H
    Cancer Sci; 2022 Jul; 113(7):2224-2231. PubMed ID: 35445479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.